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ABSTRACT The neurotropic herpesvirus varicella-zoster virus (VZV) establishes a
lifelong latent infection in humans following primary infection. The low abundance
of VZV nucleic acids in human neurons has hindered an understanding of the mech-
anisms that regulate viral gene transcription during latency. To overcome this critical
barrier, we optimized a targeted capture protocol to enrich VZV DNA and cDNA
prior to whole-genome/transcriptome sequence analysis. Since the VZV genome is
remarkably stable, it was surprising to detect that VZV32, a VZV laboratory strain
with no discernible growth defect in tissue culture, contained a 2,158-bp deletion in
open reading frame (ORF) 12. Consequently, ORF 12 and 13 protein expression was
abolished and Akt phosphorylation was inhibited. The discovery of the ORF 12 dele-
tion, revealed through targeted genome sequencing analysis, points to the need to
authenticate the VZV genome when the virus is propagated in tissue culture.
IMPORTANCE Viruses isolated from clinical samples often undergo genetic modiﬁca-
tions when cultured in the laboratory. Historically, VZV is among the most geneti-
cally stable herpesviruses, a notion supported by more than 60 complete genome
sequences from multiple isolates and following multiple in vitro passages. However,
application of enrichment protocols to targeted genome sequencing revealed the
unexpected deletion of a signiﬁcant portion of VZV ORF 12 following propagation in
cultured human ﬁbroblast cells. While the enrichment protocol did not introduce
bias in either the virus genome or transcriptome, the ﬁndings indicate the need for
authentication of VZV by sequencing when the virus is propagated in tissue culture.
KEYWORDS ORF 12, VZV, deletion, genome, transcriptome
Varicella-zoster virus (VZV) is a ubiquitous neurotropic human alphaherpesvirus.Serological studies show that over 95% of the world’s population is exposed to the
virus (1). VZV is typically acquired early in life, thereafter establishing latency in multiple
cranial and dorsal root ganglia (2) as well as thoracic sympathetic (3) and enteric (4)
ganglia. With declining cell-mediated immunity to VZV due to aging, disease, or
immunosuppressive therapy, the virus can reactivate to produce zoster (5), which is
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often complicated by persistent, dermatomal distribution pain (postherpetic neuralgia),
the leading cause of pain-related suicide in elderly patients (6). Zoster increases the risk
of stroke 2.4-fold and of myocardial infarction 1.7-fold within 2 weeks of onset (7), and
the risk remains elevated for the subsequent 3 months (8). Furthermore, VZV reactiva-
tion is associated with giant cell arteritis, the most common systemic vasculitis in the
elderly (9). The successful treatment of an immunocompetent patient with 6 years of
chronic progressive neurological disease attributed to VZV infection of the brain (10)
highlights the protean nature of VZV infections (11).
A critical barrier to the study of VZV latency is the low virus burden in naturally
infected human ganglia removed at autopsy (12) and in experimentally infected human
neurons maintained in tissue culture (13–22). While protocols to enrich VZV DNA (23)
and cDNA (24) relative to host nucleic acids have been developed, the sensitivity and
speciﬁcity provided by PCR reafﬁrms the beneﬁt of this technology for investigations
into latent VZV gene transcription and its regulation (25–28). However, extending PCR
technologies to virus whole-genome analysis requires multiple optimizations and
recalibrations to maintain primer efﬁciency in multiplex reactions involving 20 indi-
vidual amplicons (29).
The VZV genome is remarkably stable. The complete genome sequence of 66 VZV
isolates is publically available (http://www.ncbi.nlm.nih.gov/nuccore/?termvaricella
zosterviruscompletegenome), and the 124,947-  210-bp DNA can be partitioned
into 5 deﬁned clades (30), with the possible emergence of a 6th clade (31). While new
VZV isolates can be genotyped by single-nucleotide polymorphism (SNP) analysis
within VZV open reading frames (ORFs) 21 and 50 (32), VZV clades are genetic variations
that are informative for epidemiology (33–36) and evolutionary studies (37–40) but do
not describe different virus phenotypes in the human population. Naturally circulating
VZV can undergo limited recombination (31, 41), but the only phenotypic mutation
identiﬁed to date in clinical isolates is the D150N SNP in glycoprotein E, which results
in increased virus spread in cell culture (42).
VZV DNA is stable, with no detectable mutation during 16 passages in vitro after
clinical isolation (33). A total of 72 in vitro passages of the VZV32 strain introduced 31
SNPs, resulting in one codon change in ORF 33 (viral protease) and 6 codon changes
in the major immediate-early transcriptional transactivating protein (IE62) encoded by
VZV ORF 62, but these mutations did not hinder virus growth in culture (43). The 834-bp
VZV ORF 63 encoding immediate-early protein 63 (IE63) is stable, and only 3 SNPs arose
in ORF 63 between in vitro passages 1,060 and 1,206, none of which affected IE63 size,
immunoreactivity on Western blots, or virus growth characteristics in culture (44). Based
on the documented stability of VZV DNA in the human population and in tissue culture,
we developed methods to enrich VZV sequences from a background of host nucleic
acid and found an unexpected 2,158-bp deletion in ORF 12 of a VZV laboratory strain
with no discernible growth defect in tissue culture. This novel feature was discovered
only through targeted genome sequencing analysis, underscoring the need to authen-
ticate the VZV genome when the virus is propagated in tissue culture.
RESULTS
Library construction and efﬁciency of virus nucleic acid enrichment. Illumina
sequencing libraries were constructed from total DNA or RNA extracted from biological
replicates of VZV-DEN09-infected human fetal lung ﬁbroblast (HFL) cells and sequenced
pre- and postenrichment for virus nucleic acids. Infected cells were harvested 2 days
after low-multiplicity infection to ensure the presence of the full virus transcriptome, as
the virus propagated asynchronously (45). FastQC analysis to assess DNA sequence
quality for each library (data not shown) identiﬁed each nucleotide with a high degree of
conﬁdence (average per-base sequence quality score of36) and no signiﬁcant bias in GC
content (absence of peaks in average per-base sequence content). Consequently, no
end trimming of DNA sequences was required, and the entire 51-nucleotide sequence
from 2.17  108 individual sequencing events was analyzed.
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To determine virus nucleic acid enrichment efﬁciency, sequenced reads were
aligned to the reference VZV32 passage 72 (DQ479963.1) and human genome assembly
19 (https://genome.ucsc.edu/cgi-bin/hgGateway) (Table 1). On average, 97.6% of total
reads mapped to either virus or human sequences. In unenriched libraries, 20.2% 
5.9% of DNA reads and 0.44%  0.02% of cDNA reads mapped to the VZV sequence.
After targeted enrichment, the proportion of reads mapping to VZV increased to
97.7%  0.9% for DNA and 68.8%  3.3% for cDNA. An inverse linear relationship
existed between the initial abundance of virus nucleic acid present and the amount of
target DNA enrichment (Fig. 1), i.e., enrichment was greater with less virus nucleic acid.
For example, 0.4% of total cDNA sequences mapped to the VZV genome in unenriched
samples from VZV-infected HFL cells, while the amount of VZV cDNA sequences
increased 162-  5-fold after enrichment. On the other hand, the overall enrichment of
virus DNA was low when initial target DNA was abundant. For example, 24.1% of total
DNA mapped to the VZV genome in unenriched samples, while the amount of VZV DNA
sequences increased only 4% after enrichment. Nonetheless, the vast majority of DNA
sequences (83%) obtained after targeted enrichment of VZV DNA and cDNA mapped
to the virus.
TABLE 1 Alignment of DNA sequences to VZV and human genomes
Parameter
Result for sample:
A A B B C C D D
Nucleic acid used for library prepn DNA DNA DNA DNA RNA RNA RNA RNA
Targeted enrichment No Yes No Yes No Yes No Yes
Reads
Total no. 1,494,870 57,782,614 99,799,072 9,818,920 27,321,531 1,878,742 18,062,627 1,293,139
No. mapping to hg19 1,082,286 196,461 80,408,112 159,729 26,567,457 492,794 17,116,145 390,011
No. mapping to VZV strain 32 passage 72 361,609 56,834,979 15,808,173 9,531,226 122,947 1,338,040 72,251 860,067
No. of unaligned reads 50,975 751,174 3,582,787 60,877 631,127 47,908 874,231 43,062
Alignment (%) to hg19 72.40 0.34 80.57 0.62 97.24 26.23 94.76 30.16
Alignment (%) to VZV strain 32 passage 72 24.19 98.36 15.84 97.07 0.45 71.22 0.40 66.51
Unaligned (%) reads 3.41 1.30 3.59 2.31 2.31 2.55 4.84 3.33
Fold enrichment (%) of hg19 0.00 0.01 0.27 0.32
Fold enrichment (%) of VZV strain 32 passage 72 4.07 6.13 158.27 166.28
FIG 1 VZV nucleic acid enrichment dependency on initial target abundance. The fold target enrichment
(y axis) in VZV DNA (open circles) or cDNA sequences (closed circles) was plotted as a function of percent
input VZV nucleic acid in each sample. The efﬁciency of virus DNA or cDNA enrichment spanned almost
2 orders of magnitude.
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Comparison of VZV-DEN09 DNA to reference VZV32 passage 72 DNA. VZV-
DEN09 DNA sequences obtained with and without enrichment were independently
mapped to VZV32 passage 72, and the number of times that each nucleotide was
sequenced was recorded (counts per nucleotide, or cpn) (see Table S1 in the supple-
mental material). Combining the four VZV genomic sequencing events, a total of
4,175,583,047 cpn were obtained from 82,535,987 individual DNA reads, conﬁrming the
51-nucleotide read length (4,175,583,047 cpn/82,535,987 reads  50.6 nucleotides/
read). The four VZV-DEN09 DNA sequences were combined into a single database that
averaged 33,436 cpn. Differences between the reference sequence and VZV-DEN09
were identiﬁed only if the difference occurred 10,000 times at an individual site and
only if 98% of nucleotide reads at the site were identical. A total of 41 SNPs were
detected between the reference VZV DNA and VZV-DEN09, reﬂecting 0.04% of the
125,169 nucleotides in VZV32 passage 72 (Table S2). Fourteen mutations occurred in
ORF 62 and were also present in ORF 71 by virtue of the gene’s location in the repeat
region of the unique short DNA segment. There were 27 unique SNPs in VZV-DEN09, 23
of which were within unique VZV ORFs and 4 SNPs in unannotated regions of the virus
genome. The 23 SNPs included 14 synonymous mutations that would not affect protein
sequence and 9 nonsynonymous mutations resulting in predicted amino acid changes
to proteins encoded by VZV ORFs 2, 17, 51, 35, 51, and 62.
Alignment of the pooled VZV-DEN09 DNA data set to the reference genome showed
remarkably consistent read depths, with the exception of three areas (Fig. 2): area A
showed an 2-fold increase in read depth between nucleotides 800 and 3100 com-
pared to the genome average, area B indicated an 1.2-kbp DNA deletion in the
VZV-DEN09 genome, and area C indicated a 3- to 4-fold increase in read depth
compared to the genome average between nucleotides 110000 and 111700. Since area
C was located in the internal repeat of the unique short segment (IRS), the identical
sequence (area C=) is located in the inverted terminal repeat of the unique short DNA
segment (TRS) between nucleotides 120100 and 118600. Importantly, neither area C nor
C= extended throughout the internal or terminal invert repeat of the unique short
segment of the virus genome, suggesting these areas were not the result of the
mapping algorithm.
Accumulation of short VZV DNA repeats in areas A and C/C=. The overrepre-
sented VZV DNA in areas A and C/C= was conﬁrmed by quantitative PCR (qPCR). Six sets
of qPCR primers (Table 2) spanning most of the virus genome at 20-kbp intervals
were selected to establish a baseline for comparison of qPCR results obtained with
primers located within A and C/C=. Primer sets were speciﬁc for VZV DNA and produced
FIG 2 Alignment of DNA sequence from VZV-DEN09 to VZV32 passage 72. The VZV genome contains a long unique (UL) and short unique (US)
segment joined through the internal repeat of the long (IRL) and short (IRS) segments, which are inverted at the genome end as terminal repeats
of the long (TRL) and short (TRS) segments, respectively. The 51-nucleotide VZV-DEN09 reads, mapped to the archived reference strain (VZV32
passage 72) genome, showed overrepresented DNA segments at A, C, and C= along with a deletion at region B. The average read depth per
nucleotide was 24,000 (red line).
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single 40- to 46-bp amplicons with 93.03%  3.53% efﬁciency (Table 3, columns 2 to
4). Use of each of the eight PCR primer sets to quantify 2-fold dilutions of VZV bacterial
artiﬁcial chromosome (BAC) DNA revealed a 2.09-  0.91-fold dilution of target DNA
(Table 3, columns 5 to 7), indicating that qPCR could detect the predicted 2- to 4-fold
increase of VZV DNA in areas A and C/C= over baseline VZV DNA. Each of the 8 primer
sets ampliﬁed 6,000 copies of BAC-derived VZV DNA extracted from Escherichia coli to
the same extent (threshold cycle [CT] of 25.62  1.31, n  60) (Table 3, columns 8 to
11). VZV-DEN09 DNA extracted from infected cells was diluted to 6,000 copies per
PCR and ampliﬁed with the 8 sets of PCR primers. Results of 4 to 6 separate assays
showed that areas A and C/C= contained 2.22- 0.79- and 4.32- 0.70-fold more DNA,
respectively, than that detected using the six baseline primer sets (Table 3, columns 12
to 15), conﬁrming the increased presence of VZV DNA in these areas indicated by
whole-genome sequencing.
To determine whether the overrepresented virus DNA in region A (Fig. 2) resulted
from unanticipated DNA repeats present in VZV-DEN09 but not in VZV32, two inde-
pendent samples of VZV-DEN09 DNA were PCR ampliﬁed in duplicate and compared to
fragments from PCR of VZV BAC DNA extracted from E. coli (Fig. 3, left). A predicted
2.7-kbp fragment was detected in all samples. To determine if new repeat regions were
contained within the 2.7-kbp segment, the entire segment was Sanger sequenced
using sets of internal primers (Fig. 3, right). The DNA sequence for each PCR product
showed that the 2,711  6 nucleotide fragment contained no repeated segment.
The deletion in area B results in the absence of ORF 12. The DNA deletion (area
B) indicated by whole-genome sequencing was conﬁrmed by PCR using primers
located 79 and 49 nucleotides before and after the expected deletion site, respectively
(Fig. 4). An 2.3-kbp PCR band was present in VZV-DG, VZV-NASA, VZV Web A (RIT),
VZV-DEN09, and VZV-DEN13 DNA samples (Fig. 4A). While the 2.3-kbp DNA fragment
was predicted in all complete VZV genome sequences publically available and was
present in VZV-DEN09 at passage 7, albeit to a lesser extent, in HFL cells (lane 5), it was
undetectable in VZV-DEN09 after 20 passages in HFL cells (lanes 6 to 8). Instead, an
140-bp fragment was present in these samples and, to a lesser degree, in VZV-DEN13
after 2 passages in MRC-5 cells (lanes 9 and 10). The disappearance of the 2.3-kbp band
TABLE 2 Oligonucleotide primers
Name Sequence (5=–3=)
Location of
5= enda Application
5k-FOR GGATTATTGCCTGCACCTCTAA 8746 PCR
5k-REV CAGAAGCGACTACGTCTTCTAAC 8791 PCR
20k-FOR AATGCTCAGGGCACGTAAA 24248 PCR
20k-REV GCCGGAGTGTCCAGATATAAAC 24290 PCR
40k-FOR CCGTTCGGCGTATCGTATTT 40775 PCR
40k-REV TGCACGCGCTAACCATAAT 40815 PCR
60k-FOR CCCGAAGAGAGTTTGGATTACC 64941 PCR
60k-REV CGTGTGGGCCATGGATAAA 64988 PCR
80k-FOR GTTGTGAAGCGTTCCAATTCC 80249 PCR
80k-REV ACGTCATCAGGCCGTTATTC 80291 PCR
100k-FOR CCTTGGTTGCATCTCCAAGTA 100574 PCR
100k-REV CCTCTACGGGAGCAAACTAAAG 100619 PCR
Area A For CCCTTACTGCTGTCGTGGTCGCC 495 PCR
Area A Rev GGACTCACGTATTGCCCGCGCG 3344 PCR
Area A-For ﬁrst seq GTTGCCGTTTTTCCCGAGGA 501 Sequence
Area A-Rev ﬁrst seq CGTGAGAGAGTCATACGTG 3319 Sequence
Area A-For second seq CTCTGTTTATGGCGGGGTAA 1213 Sequence
Area A-Rev second seq TGTTAGGGTTGGGAGAGTGG 2383 Sequence
Area B For AGCGCGGAGTTCTTTGG 18476 PCR
Area B seq For CGCAATGTTTTCTCGGTTTGCG 16012 Sequence
Area B seq Rev CTGAAGTTCGCCGGTTAACG 18707 Sequence
Area B Rev GCGTAGCCATGCATTTACTAC 16198 PCR
Area C/C=-FOR GGAAGTGCGAACGGGTTTA 117892 PCR
Area C/C=-REV CGAAGAACTTCATATCTGAGGCA 117935 PCR
aLocation based on archive VZV strain 32 passage 72 DNA sequence (accession no. DQ479963.1).
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and appearance of the140-bp PCR product was consistent with the targeted genome
sequencing data for VZV-DEN09 after 20 passages in HFL cells (Fig. 2) and suggested
that a large deletion in VZV32 had occurred. DNA sequence analysis of the 140-bp PCR
product in lane 6 conﬁrmed the deletion of 2,160 bp from nucleotides 16269 to 18428
with respect to the VZV32 passage 72 genome (Fig. 4B).
The outcome of this deletion preserved the coding sequence for the ﬁrst 22 amino
acids of ORF 12 but removed the coding sequence for the remaining C-terminal 211
amino acids. Interestingly, the TAA termination codon that truncated ORF 12 was
generated from a fusion of TAC (tyrosine codon) of ORF 12 with the ATG (initiation
codon) of ORF 13 (Fig. 4B). Therefore, we asked if the DNA deletion in VZV-DEN09
affected the protein expression of ORFs 12 and 13. MeWo, HFL, and quiescent human
brain vascular adventitia ﬁbroblast (HBVAF) cultures were infected with VZV-DEN09 and
VZV-DEN13 for 72 h, and infection efﬁciency was quantitated by glycoprotein E (gE)
expression (Fig. 5A to D). Expression of ORFs 12 and 13 then was examined by
immunoblotting. In all three cell types, only infection with VZV-DEN13 supported
expression of ORFs 12 and 13 (Fig. 5E). Since ORF 12 protein triggers phosphorylation
of Akt (46), we also examined whether infection with VZV-DEN09 would phosphorylate
Akt through a possible ORF 12-independent, redundant pathway. HBVAFs were in-
cluded as a control because quiescence has previously been established in these cells
(47), which allows background levels of phosphorylated Akt to be kept at a minimum
(46, 48). Total Akt protein expression was similar in uninfected and infected cells.
However, while VZV-DEN13 infection induced Akt phosphorylation, no phosphorylated
Akt was detected following VZV-DEN09 infection (Fig. 5E).
The ORF 12 deletion has minimal inﬂuence on VZV replication. We examined if
loss of ORF 12 and ORF 13 proteins could inﬂuence virus replication in the cell types in
TABLE 3 Analysis of overrepresented DNA regions in VZV
Primer set ID
PCR standardization
Analysis of
2-fold diluted
VZV DNAa
CT value for 6,000 copies of VZV
DNAa
 analysis of area:
Ab C/C=c
Efﬁciency R2 n d SD n Trial 1 Trial 2 Trial 3 Trial 4 Avg n Avg n
5k 93.13 1.00 3 1.02 0.19 2 25.96 26.70 26.93 0.79 4 1.51 4
25.87 26.53 26.92
20k 90.54 1.00 3 1.19 0.06 2 26.88 26.38 26.16 1.04 4 1.76 4
26.80 26.58 26.36
40k 91.29 1.00 3 1.02 0.08 3 26.30 25.20 26.59 26.88 0.77 6 2.20 6
26.28 25.75 26.82 26.60
26.89
60k 94.61 0.98 3 1.00 0.06 3 26.38 26.46 25.54 25.98 1.58 6 3.01 6
26.10 26.50 26.27 24.46
22.67
80k 98.39 1.00 3 0.99 0.14 2 25.41 25.24 26.25 1.44 4 2.16 4
25.20 24.92 26.02
100k 93.61 0.99 3 0.97 0.06 2 25.00 26.41 26.00 1.29 4 2.01 4
24.34 26.39 25.76
Area A 86.82 1.00 3 0.97 0.31 3 23.21 26.32 26.64 25.13
22.90 26.11 26.98 24.52 0 6
26.08
Area C 95.84 1.00 3 1.34 0.65 3 26.92 24.47 21.66 23.82 0 6
26.51 24.66 22.55 23.92
22.43
Avg 93.03 0.99 3 1.06 25.62 1.15 2.11
SD 3.53 0.01 0 0.13 1.31 0.34 0.51
n 8 8 8 8 60 6 6
Fold differencee (avg) 2.09 2.22 4.32
Fold difference (SD) 0.91 0.79 0.70
N 8 6 6
aVZV DNA extracted from VZV BAC grown in E. coli.
b[CT(area A)  CT(6,000 VZV DNA copies)]  [CT(background primer set)  CT(6,000 VZV DNA copies)].
c[CT(area C/C=)  CT(6,000 VZV DNA copies)]  [CT(background primer set) CT(6,000 VZV DNA copies)].
dDifference in CT values from 2-fold dilutions of VZV DNA.
eTwo raised to the power of the absolute value Δ or ΔΔ.
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which the viruses were grown. While a minor, yet signiﬁcant, decrease in replication
was observed with VZV-DEN09 infection of MeWo cells at 4 dpi, infection of HFL cells
with VZV-DEN09 and VZV-DEN13 did not result in any discernible replication differ-
ences (Fig. 6).
Analysis of DNA sequence bias in enriched virus samples. To determine whether
DNA enrichment was uniform across the virus genome, the VZV-DEN09 cpn at each
nucleotide location was normalized and compared before and after DNA enrichment.
For each library, the cpn for the ith nucleotide was modiﬁed to reﬂect the read
originated from a 51-bp DNA sequence by summing the cpn for each position 25
nucleotides before and after the ith position. For each nucleotide, the new cpn was
divided by the maximum cpn for all positions, resulting in a normalized cpn for each
position ranging from 0 to 1. The normalized cpn for each enriched library was then
divided by the normalized cpn for each unenriched library, converted to log2 values,
and averaged for each position across all library combinations. The resulting bias value
reﬂected whether speciﬁc DNA sequences were overrepresented due to the posten-
richment 14 PCR cycles (bias value,1) or to the loss of speciﬁc DNA sequences during
target enrichment (bias value, 	1). The overall average bias value was 0.18  0.23,
suggesting a slight, but insigniﬁcant, negative bias during enrichment. Display of the
bias value for each nucleotide (Fig. 7) indicated that the only area of VZV DNA showing
a bias value of 	1 was the deletion identiﬁed as region B in Fig. 2. No bias of 2-fold
was encountered during enrichment of VZV DNA across the VZV genome.
VZV-DEN09 transcriptome. Directional cDNA libraries were constructed from total
RNA extracted from biological replicates of VZV-infected HFL cells (Table 1, samples C
and D). After sequencing, reads for each library (with or without enrichment) were
aligned to speciﬁc strands of the 123,025-bp VZV-DEN09 genome assembled from DNA
sequence data obtained as described above (Table S3). For each library, the total
number of reads divided by total cpn for each strand indicated a read length of 50.9 
0.2 nucleotides, verifying the integrity of alignment and mapping data.
To determine whether cDNA enrichment was uniform for all nucleotides across the
VZV genome, a bias value similar to that described above was determined. A total of
1.22  108 cpn were obtained, but each library was trimmed to omit 	10 cpn for
FIG 3 VZV DNA region A sequence determination. (Left) Two independent samples of VZV-DEN09 DNA (sample 1, lanes 1 and 2; sample 2, lanes 5 and 6) along
with duplicate samples of VZV BAC (lanes 3 and 4) were PCR ampliﬁed with primers ﬂanking region A. All PCR products showed similar 2.8-kbp bands. M, 500-bp
marker. (Right) The complete DNA sequence of the 2.8-kbp PCR product was assembled in two steps. Seq 1 obtained 702 to 976 nucleotides beginning at
approximately nucleotide 565 (yellow) and 936 to 998 nucleotides ending at approximately nucleotide 3275 (green). Seq 2 completed the 738 to 1070 internal
sequence (orange), with 1842 to 1869 nucleotides extending from nucleotides 712 to 738 to nucleotides 2557 to 2582 (blue).
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unenriched libraries and 	100 cpn for enriched libraries, yielding 1.10  108 cpn used
for further calculations. For each VZV DNA nucleotide, the trimmed cpn was normalized
to the maximum cpn of the related DNA strand. The bias value plot (quotient of
normalized enriched samples to normalized unenriched samples) showed the deviation
from expectation (bias value, 0) for each nucleotide (Fig. 8). A total of 73,867,869 cpn
mapped to the top strand of the virus genome, while 47,668,602 cpn mapped to the
bottom DNA strand, showing 1.55:1 top-to-bottom virus strand coding usage. For both
DNA strands, the majority of cpn (90.5% [top] and 88.7% [bottom]) showed bias values
between 1 and 1, indicating a 	2-fold relative difference between unenriched and
enriched VZV cDNA. Bias values of 	1 were obtained for 3.1% of nucleotides on the
top strand and 4.5% of nucleotides on the bottom strand of the virus genome,
indicating a 2-fold relative enrichment of cDNA at these locations. Bias values of 1
were obtained for 6.4% of nucleotides on the top strand and 6.9% of nucleotides on the
bottom strand, indicating a 2-fold enrichment of cDNA at these locations. Since cpn
reﬂects alignment of 51-bp sequencing reads, a 51-bp sliding window was generated
to map individual cpn to reads. Of the 9,435 nucleotides showing 2-fold (absolute
value) bias values, only 82 (0.9%) mapped to potential sequencing reads. To determine
whether these 82 reads were located within coding regions, the VZV-DEN09 genome
was annotated based on the archived VZV32 passage 72 genome (accession no.
DQ479963). While coding frames were shifted for some ORFs due to intergenic indels,
only the ORF 12 truncation showed a length difference compared to the archived
genome (Fig. 9). Based on the VZV-DEN09 annotation, the 5= end of the outlying
transcriptome sequencing (RNA-seq) reads were located at nucleotides 36283 (ORF 22),
60098 to 60095 (ORF 33), 119227 to 119246, and 119876 to 119894 (ORF 71). Analysis
of transcripts per million mapped reads, calculated by normalizing the sum of cpn for
FIG 4 Deletion of 2,160 bp in VZV-DEN09 ORF 12. (A) Agarose gel of PCR products generated using
primers spanning ORF 12 and VZV DNA from VZV-DG after 21 and 48 passages in MeWo cells (lanes 1
and 2, respectively), VZV-NASA after 	10 passages in HFL cells (lane 3), VZV Web A (RIT) after 50
passages in BSC-1 cells (lane 4), VZV-DEN09 after 7 passages in HFL cells (lane 5), three independent DNA
extractions of VZV-DEN09 in HFL cells after 20 passages (lanes 6 to 8), and two independent DNA
extractions of VZV-DEN13 after 2 passages in MRC-5 cells (lanes 9 and 10). M, 100-bp marker (left) and
500-bp marker (right). (B) Sequence of the ORF 12 deletion junction determined from analysis of the PCR
product from lane 6. Red nucleotides indicate newly formed ORF 12 termination codons, underlined
nucleotides indicate ORF 13 initiation codons, and numbers indicate nucleotide location of deletion
relative to archive VZV32 passage 72.
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each VZV-DEN09 ORF to ORF length followed by renormalization to total cpn, all
divided by 106, revealed no signiﬁcant difference (P  0.11 to 0.99 by t test) between
the two independent unenriched libraries and enriched libraries at any of the 74 VZV
ORFs (Table S4), indicating that targeted enrichment of VZV cDNA did not alter the
transcriptional proﬁle of the annotated VZV genes.
FIG 5 VZV-DEN09 does not express ORFs 12 or 13 and does not induce Akt phosphorylation. (A to C) Flow cytometry analyses of VZV gE
expression in mock (blue)- and VZV (red)-infected cells. Human brain vascular adventitia ﬁbroblasts (HBVAFs) (A), HFL (B), or MeWo (C) cultures
were left uninfected or infected with VZV-DEN09 or VZV-DEN13 for 72 h. (D) Graphical representation of percent VZV gE cells from panels A to
C. HBVAFs, gray; HFLs, red; MeWos, green. Error bars represent average percent VZV gE cells  standard deviations from duplicates for HBVAFs.
An asterisk denotes 0% of mock-infected cells expressed VZV gE. (E) Cell lysates were prepared for immunoblotting and resolved on 12.5%
SDS-PAGE gels. Membranes were probed for ORFs 12 and 13 and total and phospho-Akt. gE was included as an infection control, and -actin
was included as a loading control.
FIG 6 Growth analysis of VZV-DEN09 and VZV-DEN13 in MeWo and HFL cells. DNA was isolated from infected cells
(VZV-DEN09 [dashed lines] and VZV-DEN13 [solid lines]) and quantiﬁed by TaqMan-based qPCR at the indicated days
postinfection. Fold increase in VZV DNA was determined by the delta CT method, normalized to day 0 (2[CT(day 0)  CT(day X)]).
Data represent duplicate growth curves. *, P 	 0.05.
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Summation of strand-speciﬁc cpn for all libraries of VZV-DEN09 was used to develop
a transcriptome map (Fig. 10). All annotated VZV ORFs were transcribed in HFL cells,
and their steady-state abundance was ranked in order of decreasing amounts (Table 4).
To better determine relationships between transcript abundance, VZV genes were
grouped into similar temporal and functional groups based on established or predicted
homology to herpes simplex virus 1 (HSV-1). The average rank for VZV genes sorted into
temporal classes was immediate early (8.3), early (47.7), late (38.4), and unknown class
(36.8); the average rank for VZV genes sorted into functional classes was DNA replica-
tion (51.8), glycoproteins (33.0), nucleocapsid proteins (28.2), and regulation of tran-
scription (8.3). These results indicate that steady-state amounts of immediate-early VZV
gene transcripts involved in regulating virus gene transcription exceeded those of
transcripts encoded by early or late virus genes involved in DNA replication or the
structure of the virus.
DISCUSSION
Despite its global distribution and an extremely long evolutionary history, VZV DNA
is remarkably homogeneous throughout the world. The VZV mutation rate of 1  105
to 6 105 substitutions/site/year translates into	1 mutation in the 125-kbp genome
per year (35). The VZV phenotype is even more stable; the only reported clinical strain
of VZV with an altered in vitro growth phenotype has a nonsynonymous substitution in
gE, a mutation that results in increased virulence in tissue culture and skin graft cultures
(49), and is also present in an independent VZV isolate from British Columbia (42). In
tissue culture, VZV is also extremely stable. Sequencing of VZV32 after 5, 22, and 72
passages has revealed signiﬁcant sequence modiﬁcation at only 3 locations. Three
regions show expansion of DNA repeats: (i) an 8-bp region of ORF 11 at passage 5 was
duplicated at passage 22 and maintained at passage 72; (ii) a 4-copy 54-bp repeat
between ORFs 62 and 63 as well as the inverse ORFs 70 and 71 at passage 5 expanded
to ﬁve copies by passage 22 and was maintained at passage 72; and (iii) one copy of
an 18-bp duplication in ORF 22 at passage 5 was deleted by passage 22 and returned
in passage 72. Notably, all of these variations occur in regions of the virus DNA that
contain known sequence repeats, and none are contained within the origin of VZV DNA
replication. Thus, while extended in vitro propagation produces local extension or
retraction of known repeated DNA, our deep-sequence analysis of VZV-DEN09 showed
a large deletion signiﬁcantly affecting ORF 12 and 13 protein expression. In addition,
speciﬁc areas (A, C, and C=) of overrepresented DNA, conﬁrmed by multiple qPCR
FIG 7 Bias value plot for VZV-DEN09 DNA. The bias value, an index of enrichment efﬁciency, was
determined for each nucleotide of VZV-DEN09. Bias values of	0 indicate less-than-expected enrichment,
while a bias value of 0 indicates more-than-expected enrichment. A single region of VZV-DEN09 DNA
that was deleted from VZV32 was outside a 2-fold deviation (blue lines) from the average (red line).
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assays, were detected that most likely originated from fragments of virus DNA present
in the infected cell nucleus but not contained in the virus genome or in VZV DNA
prepared from E. coli as a stable bacterial artiﬁcial chromosome.
The 2,160-bp deletion in ORF 12 revealed by deep-sequence analysis represents the
largest VZV DNA deletion identiﬁed to date in virus propagated under nonselective
conditions. The 84.6-kDa tegument protein encoded by ORF 12 induces phosphoryla-
tion of ERK1/2 and Akt, which activate AP-1 and Akt pathways, respectively (46, 48).
AP-1 activation protects MeWo cells from staurosporine-induced apoptosis, and Akt
activation increases levels of cyclin B1 and D3 to force cells from stationary phase and
into M and S phases, respectively (46, 48). Sequence analysis of the ORF 12 deletion
within VZV-DEN09 showed the ﬁrst 22 codons of ORF 12 were retained but that a new
termination codon is formed from the fusion between codon 22 of ORF 12 with the
initiation codon of ORF 13. This interesting arrangement would preserve the N-terminal
22 amino acids of ORF 12 but lack the gene’s 3=-untranslated regulatory sequences. Our
FIG 8 Bias value plot for VZV-DEN09 transcripts. Bias values were determined from transcriptome analysis for all nucleotide
locations on both top and bottom DNA strands of VZV-DEN09. Bias values of 1 (red dots) indicate nucleotide locations
with 2-fold the expected counts per nucleotide (cpn) in enriched samples. Bias values of 	1 (green dots) indicate
nucleotide locations with 	2-fold less than the expected cpn in enriched samples. Bias values between 1 and 1 (black
dots) indicate nucleotide locations with cpn within 2-fold of the expected value. Percentages of total cpn that reside within
each area are listed on the right. Total numbers and locations of cpn from 51-nucleotide reads residing outside the 2-fold
expected value are listed on the right, with relative location shown by dots within blue circles.
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results, in agreement with previous ﬁndings (48), indicated that ORF 12 was required for
activation of the Akt pathway, since VZV-DEN09 infection failed to phosphorylate Akt.
ORF 13 transcription also could be affected in VZV-DEN09-infected cells, since the
2,160-bp deletion removed the entire 241-bp ORF 12/13 intergenic region that pre-
sumably contains the regulatory sequences for ORF 13 transcription. Indeed, we found
that while RNA mapping to ORF 13 was present (likely a result of a read-through event
from fused ORF 12/13), no ORF 13 protein was made. The thymidylate synthetase
FIG 9 VZV-DEN09 annotated genome. Open reading frames as annotated in reference genome VZV32 passage 72 were
mapped to 1st, 2nd, or 3rd reading frames of top (T) or bottom (B) DNA strands of VZV-DEN09.
FIG 10 VZV-DEN09 transcriptome. cDNA reads were converted to counts per nucleotide (cpn) and plotted against the top or
bottom strand of the annotated VZV-DEN09 genome. Direction and location of ORFs (red arrows) are as shown in Fig. 8.
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TABLE 4 VZV-DEN09 average transcripts per million mapped reads compared to HSV-1
ORF TPMa (avg) TPM (SD) Rank
HSV-1
homologue ORF
Temporal
classb Rank Avg rank Functional class ORF Rank Avg rank
0 6.946 1.389 32 None 70 IE 3 8.3 DNA replication 16 60 51.8
1 1.220 0.308 69 None 63 IE 4 DNA replication 28 55
2 2.563 0.343 57 None 4 IE 6 DNA replication 29 33
3 8.790 0.795 28 UL55 62 IE 9 DNA replication 36 40
4 22.000 2.256 6 UL54 71 IE 11 DNA replication 51 71
5 2.751 0.219 54 UL53 61 IE 17 Glycoproteins 5 54 33.0
6 1.417 0.057 67 UL52 48 E 14 47.7 Glycoproteins 14 74
7 2.922 0.359 53 UL1 59 E 24 Glycoproteins 31 22
8 3.755 0.453 46 UL50 29 E 33 Glycoproteins 37 37
9A 6.529 0.576 35 UL49.5 18 E 36 Glycoproteins 50 23
9 42.232 2.692 1 UL49 36 E 40 Glycoproteins 60 42
10 6.921 0.659 34 UL48 19 E 41 Glycoproteins 67 7
11 16.528 2.434 10 UL47 8 E 46 Glycoproteins 68 5
12 3.847 0.569 44 UL4 28 E 55 Nucleocapsid 21 51 28.2
13 8.310 0.891 30 None 16 E 60 Nucleocapsid 23 19
14 0.321 0.039 74 UL44 52 E 66 Nucleocapsid 33 16
15 3.426 0.070 49 UL43 6 E 67 Nucleocapsid 40 27
16 1.977 0.241 60 UL42 55 E 68 Regulate transcription 4 6 8.3
17 2.457 0.104 58 UL41 51 E 71 Regulate transcription 61 17
18 6.390 0.545 36 UL40 9 L 1 38.4 Regulate transcription 62 9
19 4.806 0.383 41 UL39 49 L 2 Regulate transcription 63 4
20 8.588 0.669 29 UL38 68 L 5 Regulate transcription 70 3
21 3.234 0.320 51 UL37 67 L 7 Regulate transcription 71 11
22 3.234 0.422 50 UL36 33.5 L 8 0 32
23 13.117 1.352 19 UL35 11 L 10 1 69
24 5.945 0.748 38 UL34 41 L 13 2 57
25 2.696 0.392 56 UL33 58 L 15 3 28
26 1.675 0.058 61 UL32 33 L 16 6 67
27 3.532 0.218 48 UL31 47 L 18 7 53
28 2.720 0.234 55 UL30 23 L 19 8 46
29 6.937 0.567 33 UL29 46 L 20 9A 35
30 1.674 0.200 62 UL28 31 L 22 9 1
31 11.910 0.666 22 UL27 50 L 23 10 34
32 12.010 1.344 21 None 64 L 25 11 10
33 13.614 1.374 16 UL26 69 L 26 12 44
33.5 18.037 2.056 8 UL26.5 40 L 27 13 30
34 4.319 0.427 43 UL25 3 L 28 15 49
35 1.660 0.254 65 UL24 20 L 29 17 58
36 5.406 0.308 40 UL23 44 L 31 18 36
37 6.330 0.326 37 UL22 10 L 34 19 41
38 5.626 0.242 39 UL21 9A L 35 20 29
39 1.115 0.077 70 UL20 37 L 37 22 50
40 8.839 1.045 27 UL19 24 L 38 24 38
41 15.740 0.793 13 UL18 38 L 39 25 56
42 1.669 0.260 64 UL15 60 L 42 26 61
43 3.012 0.324 52 UL17 34 L 43 27 48
44 7.917 0.868 31 UL16 12 L 44 30 62
45 1.673 0.078 63 UL15 53 L 45 32 21
46 13.117 1.682 20 UL14 54 L 47 33.5 8
47 13.191 1.594 18 UL13 27 L 48 34 43
48 15.054 0.967 14 UL12 15 L 49 35 65
49 38.327 1.554 2 UL1 22 L 50 38 39
50 11.103 0.715 23 UL10 21 L 51 39 70
51 0.852 0.080 71 UL9 43 L 52 41 13
52 1.518 0.132 66 UL8 7 L 53 42 64
53 3.839 0.553 45 UL7 5 L 54 43 52
54 3.539 0.572 47 UL6 25 L 56 44 31
55 1.415 0.082 68 UL5 17 L 58 45 63
56 0.835 0.177 72 UL4 66 L 59 46 20
57 16.342 1.311 12 None 26 L 61 47 18
58 14.830 0.975 15 UL3 30 L 62 48 14
59 10.028 0.958 24 UL2 45 L 63 49 2
60 4.456 0.162 42 UL1 42 L 64 52 66
61 13.237 0.310 17 ICP0 35 L 65 53 45
(Continued on next page)
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encoded by VZV ORF 13 is dispensable for virus propagation (50) and is a prime site for
targeted insertion of foreign genes (51, 52). The nonessential nature of ORF 12 and ORF
13 proteins is echoed by our growth analysis, in which we did not observe a replication
defect in HFL cells infected with VZV-DEN09. However, a slight decrease in replication
was apparent in infected MeWo cells at later times postinfection. Since MeWo cells were
derived from a malignant melanoma, these ﬁndings suggest that the ORF 12 and ORF
13 proteins serve different functions in normal and cancer cell lines.
The VZV lytic transcriptome has been analyzed by PCR-based (53) and long
oligonucleotide-based (54) arrays, by multiplex PCR (29), and by next-generation cDNA
sequencing (55–57). While differences in transcript proﬁles are noted depending on cell
type, time of harvest, and technique used, general themes emerge when the data are
restricted to RNA-seq ﬁndings during lytic VZV infection. Combining published RNA-seq
data derived from VZV-infected HFL cells or human neurons in culture with results in
the present study showed individual differences in transcript abundance. For example,
the ﬁve most abundant transcripts (in decreasing order) map to ORFs 57, 9, 68, 58, and
63 (55), ORFs 57, 49, 9, 68, and 67 (22), and ORFs 9, 49, 63, 68, and 4 (this study);
however, when virus gene classes are analyzed, all studies identify immediate-early
transcripts as the most abundant, followed by late and early transcripts. Similarly,
transcripts that regulate virus gene transcription are the most abundant, followed by
transcripts encoding glycoproteins, nucleocapsid proteins, and, ﬁnally, proteins in-
volved in virus DNA replication (Table 5). In addition to determining steady-state
amounts of previously mapped virus genes, RNA-seq analysis can indicate the presence
of novel virus transcriptional units. For example, RNA mapping to the unannotated
1.4-kbp region between VZV ORFs 60 and 61 has been detected by Northern blot (58)
and array (53) analyses, and preliminary cloning results suggest extensive splicing of
TABLE 4 (Continued)
ORF TPMa (avg) TPM (SD) Rank
HSV-1
homologue ORF
Temporal
classb Rank Avg rank Functional class ORF Rank Avg rank
62 16.548 3.813 9 ICP4 39 L 70 54 47
63 34.880 4.937 4 us1.5 56 L 72 55 68
64 9.462 2.572 25 us10 65 L 73 56 72
65 0.784 0.165 73 us9 14 L 74 57 12
66 2.160 0.190 59 us3 57 U 12 36.8 58 15
67 18.250 1.183 7 us7 32 U 21 59 24
68 31.449 1.539 5 us8 13 U 30 64 25
69 9.259 2.643 26 us10 0 U 32 65 73
70 35.131 4.209 3 us1.5 2 U 57 66 59
71 16.447 3.946 11 ICP4 1 U 69 69 26
aTPM, transcripts per million reads.
bIE, immediate early; E, early; L, late; U, unknown.
TABLE 5 Comparison of RNA-seq data for VZV during lytic infection in culture
Classd
Avg rank by cell type
Fibroblasta Fibroblastb Neuronb Neuronc
Temporal
Immediate early (4) 7.3 13.0 12.5 20.5
Early (13) 42.0 45.2 42.8 43.4
Late (44) 33.4 32.0 32.7 32.1
Functional
DNA replication (5) 45.8 52.2 48.4 49.2
Glycoproteins (7) 23.4 21.0 23.3 21.0
Nucleocapsid (4) 24.3 26.8 32.3 33.0
Regulate transcription (4) 7.3 13.0 12.5 20.5
aData are from this study.
bData are from reference 55.
cData are from reference 21.
dNumbers in parentheses indicate the number of VZV genes within each class.
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short segments into single polyadenylated virus transcripts within this region (unpub-
lished data). Mapping our current RNA-seq data to this region revealed multiple short
and low-abundance RNA segments on the opposite coding strand of ORFs 60 and 61
(Fig. 11).
Overall, we have developed a technique to enrich low-abundance VZV DNA and
cDNA in an unbiased manner; consequently, we identiﬁed a deletion in the coding
region of a VZV gene which occurred through normal (no intentional selective pressure)
in vitro propagation. Comparison of available RNA-seq data showed differences in
individual gene transcript amounts but concordance at the level of gene groupings.
Interestingly, transcripts mapping to immediate-early genes functionally identiﬁed as
regulators of gene transcription were the most abundant transcriptional group de-
tected during lytic infection in human ﬁbroblasts or neurons harvested 2 days to 2
weeks postinfection, suggesting that the continuous presence of virus transactivators
is required as the infection spreads throughout the culture.
The unique features of VZV propagated in vitro, as revealed by whole-genome
analysis of VZV DNA and transcripts, raises several interesting questions. For example,
how did the ORF 12 deletion develop, and what is its consequence on activation of
cellular immediate-early response pathways? What mechanism leads to the overrepre-
sented DNA that was identiﬁed by deep sequencing and conﬁrmed by qPCR? Answers
to these questions await further investigation.
In summary, the discovery of the ORF 12 deletion affecting ORF 12 and 13 protein
production in the VZV-DEN09 strain of VZV32, revealed through whole-genome anal-
ysis, points to the need to authenticate the VZV genome when the virus is propagated
in tissue culture. While this deletion appears to be restricted to VZV32, our data suggest
that high passage can lead to changes in what is believed to be a stable VZV genome.
MATERIALS AND METHODS
Cells and virus. Human fetal lung ﬁbroblasts (HFL; ATCC-CCL-153), MeWo malignant melanoma cells
(59), and MRC-5 human lung ﬁbroblasts (ATCC CCL-171) were grown in Dulbecco’s modiﬁed Eagle
medium (Invitrogen, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS; HyClone, Logan,
UT). Primary human brain vascular adventitia ﬁbroblasts (HBVAFs) were grown in 2% FBS, 1% ﬁbroblast
growth serum, and 1% 100 penicillin-streptomycin in basal ﬁbroblast medium (Sciencell, Carlsbad, CA)
as previously described (47). After 24 h, the medium was changed to 0.1% FBS for 6 to 7 days to establish
quiescence.
VZV32 (provided to R. J. Cohrs in 2009 by Charles Grose, University of Iowa) was propagated in MeWo
cells for 50 passages and transferred as Dounce-homogenized cell-free virus (60) into HFL cells. This
virus was designated VZV-DEN09 to uniquely identify the virus DNA and cDNA sequences analyzed in the
current study. VZV32 (provided to K. S. Lee in 2013 by Charles Grose) was also propagated in a separate
FIG 11 Location of candidate novel VZV transcripts. Enlargement of the 1.4-kbp ORF 60/61 intergenic
segment of VZV-DEN09 shown in Fig. 9 revealed three locations of increased cpn (arrows) on the DNA
strand (black) opposite that encoding ORFs 60 and 61 (red).
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laboratory for 	3 passages in MRC-5 cells and designated VZV-DEN13. VZV-DG, a clinical isolate from a
zoster lesion, was propagated in MeWo cells. The VZV Web A (RIT) strain was isolated from the vesicle
of a patient with varicella and cultivated in human ﬁbroblasts, WI-38 and MRC-5 cells (61), before the
virus was transferred (62) and propagated in BSC-1 African green monkey kidney cells (63). VZV-NASA,
isolated from saliva of an astronaut 1 day after spaceﬂight, was propagated for	20 passages in HFL cells
(64). VZV BAC is the parental Oka virus strain containing the bacterial artiﬁcial chromosome initially
propagated in MeWo cells (19) and subsequently transferred to HFL cells. All VZV isolates were
propagated by cocultivation of infected and uninfected cells and never processed on the same day.
Virus nucleic acid extraction and library preparation. Chromatin harvested from VZV-infected HFL
cells at 2 days postinfection (dpi) was formaldehyde cross-linked (65) and sheered to an average size of
250 to 500 bp by isothermic sonication at 4°C for 16 min with 200 bursts/min at 140 W/burst (E220;
Covaris, Inc., Woburn, MA, USA). DNA-containing virus nucleocapsids were removed by 30 min of
centrifugation at 40,000  g at 4°C (66). Formaldehyde cross-links were reversed at 65°C for 1.5 h in 0.2
M NaCl, and DNA was extracted by afﬁnity chromatography (QIAquick PCR clean up kit; Qiagen, Valencia,
CA, USA). Libraries for DNA sequence analysis were constructed using the KAPA Hyper Prep kit (Kapa
Biosystems, Wilmington, MA, USA). For construction of cDNA libraries, total RNA was extracted (TriPure;
Roche, San Francisco, CA, USA) at 2 dpi from biological replicates of VZV-DEN09-infected HFL cells and
DNase treated (Turbo-DNase; Thermo-Fisher, Grand Island, NY, USA), and directional, rRNA-depleted
cDNA libraries were constructed (NEBNext Ultra directional RNA library prep kit; New England BioLabs,
Ipswich, MA, USA). Each sample from both the DNA and cDNA libraries was divided into two aliquots.
One aliquot was used for virus-speciﬁc target enrichment (SeqCap EZ System; Roche, Madison, WI, USA)
as described below, while the other aliquot was processed without enrichment.
Virus-speciﬁc nucleic acid enrichment. Single-strand biotinylated probes covering 99.2% of the
VZV genome (accession no. DQ452050.1) were designed with the NimbleGen SeqCap EZ Developer
(Roche). Hybridization of VZV-infected HFL DNA or cDNA libraries to the biotinylated capture probes with
subsequent washings and elution were performed according to the manufacturer’s recommendations
(SeqCap EZ SR User’s Guide v5.0; Roche).
DNA and RNA sequence analysis. All libraries were subjected to single-end 50-bp sequencing using
an Illumina HiSeq4000 (San Diego, CA, USA). Resulting fastq ﬁles were mapped to VZV (strain 32 passage
72 [accession no. DQ479963] and VZV-DEN09) genomes using Bowtie2 (with default arguments) and
SeqMan Pro (DNAStar, Madison, WI, USA).
PCR. Oligonucleotide primers (Table 2) synthesized by Integrated DNA Technology (IDT; Coralville,
Iowa, USA) were designed using VZV Dumas (accession no. X04370.1) as the template for standard and
quantitative PCR (65).
Flow cytometry.Mock- and VZV-infected MeWo, HFL, and HBVAF cultures at 72 h postinfection (hpi)
were washed with ﬂuorescence-activated cell sorter (FACS) buffer (phosphate-buffered saline [PBS]
containing 1% FBS) and stained with mouse anti-VZV-gE R-phycoerythrin (Millipore) for 30 min at 4°C,
washed with FACS buffer, and ﬁxed with 1% paraformaldehyde. Isotype controls were used in staining.
Cells were analyzed using an LSR-II ﬂow cytometer (BD Immunocytometry Systems, San Jose, CA); more
than 15,000 events were collected for all samples. Subsequent data were analyzed using Diva software
(BD Biosciences) and FlowJo software (Tree Star, Ashland, OR).
Immunoblotting. VZV-infected and control HBVAF, MeWo, and HFL cells were harvested at 72 hpi
with 0.25% trypsin-EDTA (25200-056; Life Technologies). The harvested cells were washed once with PBS
and centrifuged at 1,500 rpm for 5 min at 4°C, resuspended in E1A lysis buffer (50 mM HEPES, pH 7.2,
250 mM NaCl, 2 mM EDTA, 0.1% NP-40, 1 mM dithiothreitol [DTT], 1 g/ml aprotinin, 1 g/ml leupeptin,
50 g/ml phenylmethylsulfonyl ﬂuoride [PMSF], and 10 mM NaF), and kept on ice for 20 min. The lysates
were clariﬁed at 14,000 rpm for 10 min at 4°C. Total protein concentrations were determined using the
DCTM protein assay (Bio-Rad Laboratories, Hercules, CA). Twenty-microgram aliquots of lysates were
resolved on 12.5% SDS-PAGE gels, transferred onto polyvinylidene diﬂuoride (PVDF) membranes, and
probed for VZV ORF 12 (mouse anti-VZV ORF 12; 1:1000; Center for Proteomics, University of Rijeka,
Croatia), VZV ORF13 (mouse anti-ORF 13; 1:1,000; Center for Proteomics, University of Rijeka, Croatia), Akt
(rabbit anti-Akt; 1:1000; no. 4685; Cell Signaling Technology), phosphorylated Akt (rabbit anti-Akt
[Thr308], 1:1,000; no. 13038; Cell Signaling Technology), VZV glycoprotein E (gE; mouse anti-gE; 1:500;
sc-56995; Santa Cruz Biotechnology), and -actin (mouse anti--actin; 1:10,000; no. 3700; Cell Signaling
Technology), followed by appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies
(Santa Cruz Biotechnology). The blots were incubated with Amersham ECL Select Western blotting
detection reagent (RPN2235; GE Healthcare) and visualized with the ChemiDoc XRS system (Bio-Rad).
Viral DNA replication. HFL and MeWo cells were seeded in 6-well plates at 40% conﬂuence. Both
cell lines were infected (multiplicity of infection of 0.001) with VZV-DEN09 or VZV-DEN13 (propagated in
their respective cell lineage) after lysis through a 28-gauge needle. Virus inoculum was adsorbed for 2.5 h
at 37°C with occasional rocking, washed twice with PBS cultures, and replenished with growth medium.
Cells were trypsinized at 0, 2, 3, and 4 dpi, and nucleic acid was extracted from the harvested cells (Zymo
Duet DNA/RNA kit; Zymo Research, Irvine, CA). PCR was performed with primers and probes speciﬁc for
VZV ORF68 (Table 2) using a 7500 fast-real-time PCR system (Applied Biosystems, Thermo Fisher
Scientiﬁc, Grand Island, NY). Statistical signiﬁcance was determined using a Student’s paired t test.
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